Efficacy of repeated intravenous injection of peramivir against influenza a (H1N1) 2009 virus infection in immunosuppressed mice

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 5, 2013, Pages 2286-2294

  Kitano, Mitsutaka ^a,c   Kodama, Makoto ^a   Itoh, Yasushi ^c   Kanazu, Takushi ^b   Kobayashi, Masanori ^a   Yoshida, Ryu ^a   Sato, Akihiko ^a  

^a Infectious Diseases   (Japan)

^b Drug Metabolism and Pharmacokinetics   (Japan)

^c SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; OSELTAMIVIR; PERAMIVIR; SIALIDASE; TUMOR NECROSIS FACTOR ALPHA;

2009 H1N1 INFLUENZA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFICACY; ENZYME INHIBITION; FEMALE; HISTOPATHOLOGY; IC 50; IMMUNE DEFICIENCY; LUNG; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPEATED DRUG DOSE; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; VIRUS REPLICATION; VIRUS VIRULENCE; WEIGHT REDUCTION;

ANIMALS; ANTIVIRAL AGENTS; BODY WEIGHT; CYCLOPENTANES; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; FEMALE; GUANIDINES; IMMUNOSUPPRESSIVE AGENTS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INJECTIONS, INTRAVENOUS; LUNG; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; OSELTAMIVIR; PHOSPHOROUS ACIDS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84876226495     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02324-12     Document Type: Article

References (35)

1. Itoh Y, Shinya K, Kiso M, Watanabe T, Sakoda Y, Hatta M, Muramoto Y, Tamura D, Sakai-Tagawa Y, Noda T, Sakabe S, Imai M, Hatta Y, Watanabe S, Li C, Yamada S, Fujii K, Murakami S, Imai H, Kakugawa S, Ito M, Takano R, Iwatsuki-Horimoto K, Shimojima M, Horimoto T, Goto H, Takahashi K, Makino A, Ishigaki H, Nakayama M, Okamatsu M, Takahashi K, Warshauer D, Shult PA, Saito R, Suzuki H, Furuta Y, Yamashita M, Mitamura K, Nakano K, Nakamura M, Brockman- Schneider R, Mitamura H, Yamazaki M, Sugaya N, Suresh M, Ozawa M, Neumann G, Gern J, Kida H, Ogasawara K, Kawaoka Y. 2009. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 460:1021-1025.
2. Jain S, Benoit SR, Skarbinski J, Bramley AM, Finelli L. 2012. Influenzaassociated pneumonia among hospitalized patients with 2009 pandemic influenza A (H1N1) virus - United States, 2009. Clin. Infect. Dis. 54: 1221-1229.
3. Maines TR, Jayaraman A, Belser JA, Wadford DA, Pappas C, Zeng H, Gustin KM, Pearce MB, Viswanathan K, Shriver ZH, Raman R, Cox NJ, Sasisekharan R, Katz JM, Tumpey TM. 2009. Transmission and pathogenesis of swine-origin 2009 A(H1N1) influenza viruses in ferrets and mice. Science 325:484-487.
4. Ministry of Health, Welfare and Labour Japan. 2010. Infectious Diseases Weekly Report Japan (IDWR) 12:10-5. Ministry of Health Welfare and Labour Japan, Tokyo, Japan. http://idsc.nih.go.jp/idwr/kanja/idwr/idwr2010 /idwr2010-10.
5. Sugaya N, Shinjoh M, Mitamura K, Takahashi T. 2011. Very low pandemic influenza A (H1N1) 2009 mortality associated with early neuraminidase inhibitor treatment in Japan: analysis of 1000 hospitalized children. J. Infect. 63:288-294.
6. Bantia S, Kellogg D, Parker C, Upshaw R, Ilyushina NA, Babu YS. 2011. A single intramuscular injection of neuraminidase inhibitor peramivir demonstrates antiviral activity against novel pandemic A/California/04/ 2009 (H1N1) influenza virus infection in mice. Antiviral Res. 90:17-21.
7. Kiso M, Shinya K, Shimojima M, Takano R, Takahashi K, Katsura H, Kakugawa S, Le MT, Yamashita M, Furuta Y, Ozawa M, Kawaoka Y. 2009. Characterization of oseltamivir-resistant H1N1 pandemic influenza A viruses. PLoS Pathog. 6:e1001079. doi:10.1371/journal.ppat.1001079.
8. Nguyen HT, Sheu TG, Mishin VP, Klimov AI, Gubareva LV. 2010. Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. Antimicrob. Agents Chemother. 54:3671-3677.
9. Ljungman P, Andersson J, Aschan J, Barkholt L, Ehrnst A, Johansson M, Weiland O. 1993. Influenza A in immunocompromised patients. Clin. Infect. Dis. 17:244-247.
10. Rocha E, Cox NJ, Black RA, Harmon MW, Harrison CJ, Kendal AP. 1991. Antigenic and genetic variation in influenza A (H1N1) virus isolates recovered from a persistently infected immunodeficient child. J. Virol. 65:2340-2350.
11. Harper SA, Bradley JS, Englund JA, File TM, Gravenstein S, Hayden FG, McGeer AJ, Neuzil KM, Pavia AT, Tapper ML, Uyeki TM, Zimmerman RK. 2009. Seasonal influenza in adults and children - diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 48:1003-1032.
12. Kaiser L, Keene ON, Hammond JM, Elliott M, Hayden FG. 2000. Impact of zanamivir on antibiotic use for respiratory events following acute influenza in adolescents and adults. Arch. Intern. Med. 160:3234-3240.
13. Baz M, Abed Y, McDonald J, Boivin G. 2006. Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child. Clin. Infect. Dis. 43:1555-1561.
14. Gubareva LV, Matrosovich MN, Brenner MK, Bethell RC, Webster RG. 1998. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J. Infect. Dis. 178:1257-1262.
15. Ison MG, Gubareva LV, Atmar RL, Treanor J, Hayden FG. 2006. Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. J. Infect. Dis. 193:760-764.
16. Memoli MJ, Hrabal RJ, Hassantoufighi A, Eichelberger MC, Taubenberger JK. 2010. Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts. Clin. Infect. Dis. 50:1252-1255.
17. van der Vries E, Stelma FF, Boucher CA. 2010. Emergence of a multidrug- resistant pandemic influenza A (H1N1) virus. N. Engl. J. Med. 363: 1381-1382.
18. Kohno S, Kida H, Mizuguchi M, Shimada J. 2010. Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection. Antimicrob. Agents Chemother. 54:4568-4574.
19. Kohno S, Yen MY, Cheong HJ, Hirotsu N, Ishida T, Kadota J, Mizuguchi M, Kida H, Shimada J. 2011. Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection. Antimicrob. Agents Chemother. 55:5267-5276.
20. Food and Drug Administration. 2009. News and events: FDA authorizes emergency use of intravenous antiviral peramivir for 2009 H1N1 influenza for certain patients, settings. Food and Drug Administration, Washington, DC. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements /ucm187813.htm.
21. Kohno S, Kida H, Mizuguchi M, Hirotsu N, Ishida T, Kadota J, Shimada J. 2011. Intravenous peramivir for treatment of influenza A and B virus infection in high-risk patients. Antimicrob. Agents Chemother. 55:2803-2812.
22. Mastino A, Grelli S, Premrov MG, Favalli C. 1991. Susceptibility to influenza A virus infection in mice immunosuppressed with cyclophosphamide. J. Chemother. 3:156-161.
23. Hurd J, Heath RB. 1975. Effect of cyclophosphamide on infections in mice caused by virulent and avirulent strains of influenza virus. Infect. Immun. 11:886-889.
24. Singer SH, Noguchi P, Kirschstein RL. 1972. Respiratory diseases in cyclophosphamide-treated mice. II. Decreased virulence of PR8 influenza virus. Infect. Immun. 5:957-960.
25. Sidwell RW, Bailey KW, Morrey JD, Wong MH, Baldwin TJ, Smee DF. 2003. Inhibition of influenza virus infections in immunosuppressed mice with orally administered peramivir (BCX-1812). Antiviral Res. 60:17-25.
26. Hurt AC, Holien JK, Barr IG. 2009. In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. Antimicrob. Agents Chemother. 53:4433-4440.
27. Okomo-Adhiambo M, Sleeman K, Ballenger K, Nguyen HT, Mishin VP, Sheu TG, Smagala J, Li Y, Klimov AI, Gubareva LV. 2010. Neuraminidase inhibitor susceptibility testing in human influenza viruses: a laboratory surveillance perspective. Viruses 2:2269-2289.
28. Ward P, Small I, Smith J, Suter P, Dutkowski R. 2005. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J. Antimicrob. Chemother. 55(Suppl 1):i5-i21.
29. Baskerville A, Thomas G, Wood M, Harris WJ. 1974. Histology and ultrastructure of metaplasia of alveolar epithelium following infection of mice and hamsters with influenza virus. Br. J. Exp. Pathol. 55:130-137.
30. Betsuyaku T, Fukuda Y, Parks WC, Shipley JM, Senior RM. 2000. Gelatinase B is required for alveolar bronchiolization after intratracheal bleomycin. Am. J. Pathol. 157:525-535.
31. Li W, Escarpe PA, Eisenberg EJ, Cundy KC, Sweet C, Jakeman KJ, Merson J, Lew W, Williams M, Zhang L, Kim CU, Bischofberger N, Chen MS, Mendel DB. 1998. Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071. Antimicrob. Agents Chemother. 42:647-653.
32. Kitano M, Itoh Y, Kodama M, Ishigaki H, Nakayama M, Ishida H, Baba K, Noda T, Sato K, Nihashi Y, Kanazu T, Yoshida R, Torii R, Sato A, Ogasawara K. 2011. Efficacy of single intravenous injection of peramivir against influenza B virus infection in ferrets and cynomolgus macaques. Antimicrob. Agents Chemother. 55:4961-4970.
33. Bantia S, Parker CD, Ananth SL, Horn LL, Andries K, Chand P, Kotian PL, Dehghani A, El-Kattan Y, Lin T, Hutchison TL, Montgomery JA, Kellog DL, Babu YS. 2001. Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir. Antimicrob. Agents Chemother. 45:1162-1167.
34. Abed Y, Pizzorno A, Boivin G. 2012. Therapeutic activity of intramuscular peramivir in mice infected with a recombinant influenza A/WSN/33 (H1N1) virus containing the H275Y neuraminidase mutation. Antimicrob. Agents Chemother. 56:4375-4380.
35. Shetty AK, Peek LA. 2012. Peramivir for the treatment of influenza. Expert Rev. Anti Infect. Ther. 10:123-143.